Virios Therapeutics Llc
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for… Read more
Virios Therapeutics Llc (VIRI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.259x
Based on the latest financial reports, Virios Therapeutics Llc (VIRI) has a cash flow conversion efficiency ratio of -0.259x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-811.75K) by net assets ($3.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Virios Therapeutics Llc - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how Virios Therapeutics Llc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Virios Therapeutics Llc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virios Therapeutics Llc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PHILOGEN S.P.A.
F:78Q
|
N/A |
|
Penn Bancshares Inc
PINK:PEBA
|
N/A |
|
MS&AD INSURANCE
MU:59M
|
N/A |
|
DDFO
BATS:DDFO
|
N/A |
|
OCEANEERING INTL
BE:OII
|
0.131x |
|
IRACX
NMFQS:IRACX
|
N/A |
|
REGIONS FINANCIAL (RN7.SG)
STU:RN7
|
0.067x |
|
Antiaging Quantum Living Inc.
PINK:AAQL
|
-0.070x |
Annual Cash Flow Conversion Efficiency for Virios Therapeutics Llc (2018–2023)
The table below shows the annual cash flow conversion efficiency of Virios Therapeutics Llc from 2018 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.81 Million | $-4.87 Million | -1.279x | +18.26% |
| 2022-12-31 | $7.33 Million | $-11.47 Million | -1.565x | -44.67% |
| 2021-12-31 | $14.50 Million | $-15.69 Million | -1.082x | -731.66% |
| 2020-12-31 | $29.94 Million | $-3.90 Million | -0.130x | -130.73% |
| 2019-12-31 | $-4.94 Million | $-2.09 Million | 0.423x | -55.39% |
| 2018-12-31 | $-1.26 Million | $-1.20 Million | 0.949x | -- |